EGFR and head and neck cancer: Although a rash induced by other EGFR TKIs (e.g., erlotinib or gefitinib) has been predictive of favorable clinical efficacy in lung, pancreas, and head and neck cancers,19, 20, 21, 22 it remains unclear if a lapatinib‐induced rash is associated with treatment efficacy.